simendan has been researched along with mocetinostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altunkan, Z; Apa, D; Balli, E; Bilgin, E; Birbicer, H; Doruk, N; Oral, U; Ozeren, M; Tamer, L; Yapici, D | 1 |
| Adam, M; Baldus, S; Costard-Jäckle, A; Klinke, A; Knors, H; Meyer, S; Radunski, UK; Rudolph, TK; Rudolph, V; Spin, JM; Tsao, PS | 1 |
2 other study(ies) available for simendan and mocetinostat
| Article | Year |
|---|---|
Effects of levosimendan on myocardial ischaemia-reperfusion injury.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Hydrazones; Male; Malondialdehyde; Myocardial Contraction; Myocardial Reperfusion Injury; Myocardium; Peroxidase; Pyridazines; Rats; Rats, Wistar; Simendan; Sodium-Potassium-Exchanging ATPase | 2008 |
Levosimendan displays anti-inflammatory effects and decreases MPO bioavailability in patients with severe heart failure.
Topics: Anti-Inflammatory Agents; Biomarkers; Blood Pressure; Cardiotonic Agents; Cell Degranulation; Female; Heart Failure; Humans; Hydrazones; Inflammation; Leukocytes; Male; Middle Aged; Neutrophils; Nitric Oxide; Peroxidase; Pyridazines; Severity of Illness Index; Simendan; Time Factors | 2015 |